ClinicalTrials.Veeva

Menu

The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

S

Shiraz University of Medical Sciences

Status

Completed

Conditions

Hyperphosphatemia

Treatments

Drug: Mg Oxide

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

Enrollment

42 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

hemodialysis with duration>3 months serum P level >5.5 mg/dl serum Ca>8 mg/dl.

Exclusion criteria

Mg level >3 mg/dl

Trial design

42 participants in 2 patient groups

Mg Oxide
Description:
Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
Treatment:
Drug: Mg Oxide
placebo
Description:
placebo 1 tab TDS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems